Testing Crizotinib as a Potential Targeted Treatment in Cancers With ALK Genetic Changes (MATCH-Subprotocol F)
Clinical trial NCT04439266 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT04439266
- Sponsor
- National Cancer Institute (NCI)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2015-08-12
- Primary completion
- 2020-03-20
- Enrollment
- 5
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.